Percentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)TDM-1(Ado-trastuzumabemtansine)TNBCTC (docetaxel /cyclophosphamide)Intermediate(11-25)2yearsPembrolizumab10yearsVenlafaxinePertuzumabCapecitabineEverymonthLoperamideprophylaxisAnthracyclinesRadiationtherapyTaxanesTamoxifen1yearOlaparibExemestaneChemoendocrinetherapyLVEFmonitoringAromataseinhibitorsAbemaciclibPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)TDM-1(Ado-trastuzumabemtansine)TNBCTC (docetaxel /cyclophosphamide)Intermediate(11-25)2yearsPembrolizumab10yearsVenlafaxinePertuzumabCapecitabineEverymonthLoperamideprophylaxisAnthracyclinesRadiationtherapyTaxanesTamoxifen1yearOlaparibExemestaneChemoendocrinetherapyLVEFmonitoringAromataseinhibitorsAbemaciclib

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  2. TDM-1 (Ado-trastuzumab emtansine)
  3. TNBC
  4. TC (docetaxel / cyclophosphamide)
  5. Intermediate (11-25)
  6. 2 years
  7. Pembrolizumab
  8. 10 years
  9. Venlafaxine
  10. Pertuzumab
  11. Capecitabine
  12. Every month
  13. Loperamide prophylaxis
  14. Anthracyclines
  15. Radiation therapy
  16. Taxanes
  17. Tamoxifen
  18. 1 year
  19. Olaparib
  20. Exemestane
  21. Chemoendocrine therapy
  22. LVEF monitoring
  23. Aromatase inhibitors
  24. Abemaciclib